ADMIT THERAPEUTICS, S.L.

ADmit Therapeutics is a Spanish biotechnology company and a spin-off of the Bellvitge Biomedical Research Institute (IDIBELL), founded in Barcelona in 2017. The company is at the forefront of early Alzheimer’s disease detection through the development of innovative, minimally invasive technologies based on Artificial Intelligence (AI) and epigenetics. Its fundamental mission is to facilitate early interventions by acting proactively before irreversible neurodegenerative symptoms appear. To achieve this, the company seeks to transform the current Alzheimer’s paradigm by improving clinical patient management in healthcare practice. This allows health systems to perform efficient triage, avoid unnecessary invasive tests, and personalize medical follow-up from the early stages of the disease, while also optimizing patient selection for clinical trials.
The company’s primary asset is the MAP-AD® Test, an in vitro diagnostic (IVD) device with CE marking under the new European IVDR regulation. This technology analyzes mitochondrial DNA (mtDNA) methylation patterns in whole blood samples using Next-Generation Sequencing (NGS). By combining these epigenetic biomarkers with clinical risk factors and cognitive assessments through a machine learning algorithm, the test predicts the probability of progression to Alzheimer’s dementia in patients with Mild Cognitive Impairment (MCI). The company holds CAP/CLIA accreditation for its laboratory, being the first in Spain to obtain this American seal of excellence, which facilitates its expansion into the international market. ADmit Therapeutics drives a real transition toward personalized and precision medicine, improving healthcare system efficiency and the quality of life for patients.